• Cisplatin (CDDP): Mechanisms and Benchmarks in Cancer Resear

  2026-07-15

  Cisplatin (CDDP) is a benchmark chemotherapeutic agent that exerts antitumor activity via DNA crosslinking and caspase-dependent apoptosis. Its unique molecular actions make it indispensable for cancer research, apoptosis assay development, and modeling chemotherapy resistance.

• (S)-(+)-Ibuprofen in Cell Assays: Precision, Protocols, and

  2026-07-15

  This article provides scenario-driven, evidence-based guidance for biomedical researchers and lab technicians using (S)-(+)-Ibuprofen (SKU B1018) in cell viability and inflammation pathway studies. Drawing on numerical benchmarks, workflow troubleshooting, and comparative analysis, it details how this enantiomeric COX inhibitor from APExBIO supports reproducible, sensitive results and robust experimental design.

• Baricitinib (LY3009104) for Precision JAK1/2 Inhibition Work

  2026-07-14

  Baricitinib (LY3009104) enables selective, potent JAK1/2 blockade for dissecting cytokine signaling in inflammation models. This article delivers concrete protocols, advanced troubleshooting, and actionable insights—anchored by new spatial proteomics data—empowering immunology and translational researchers.

• Targeting NUAK1-Mediated Tau Phosphorylation in Alzheimer’s

  2026-07-14

  This study reveals a direct association between tau phosphorylation at Ser356 and Alzheimer’s disease pathology, highlighting the contribution of NUAK1 kinase activity to neurofibrillary tangle formation. Using the selective NUAK1/2 inhibitor WZ4003, the authors demonstrate reduced p-tau Ser356 in brain slice models, providing mechanistic insight for therapeutic strategies targeting tauopathies.

• Resiquimod (R-848): Translating TLR Activation Into Curative

  2026-07-13

  Explore how Resiquimod (R-848) is redefining cancer immunotherapy and ablation safety, bridging advanced mechanistic insights with actionable protocol strategies for translational researchers. Learn from pivotal hydrogel-based delivery breakthroughs, understand the competitive landscape, and discover practical guidance for leveraging this dual TLR7/8 agonist in next-generation chemo-immunomodulatory workflows.

• Cyclosporin A (B1922): Technical Guidance for Lab Research

  2026-07-13

  Cyclosporin A is a potent cyclophilin inhibitor used to suppress immune responses, modulate apoptosis, and study mitochondrial and viral mechanisms in cellular and animal research. It is best suited for experiments requiring precise immunosuppression or apoptosis modulation, but should be avoided where water solubility or long-term solution stability is needed. Adhering to protocol and storage guidelines helps ensure reproducible results.

• Ruxolitinib (INCB018424): Precision Modulation of JAK-STAT i

  2026-07-12

  Explore how Ruxolitinib (INCB018424) empowers myeloproliferative disorder research through ATP-competitive JAK-STAT inhibition. This article uniquely connects advanced kinase targeting with experimental immunomodulation, offering new insights for assay design and translational studies.

• (S)-(+)-Ibuprofen: COX Inhibitor Workflows and Advanced Use-

  2026-07-10

  (S)-(+)-Ibuprofen empowers researchers with precise control over inflammation and pain pathways, thanks to its superior COX selectivity and robust pharmacological profile. This guide delivers actionable protocols, troubleshooting insights, and an in-depth look at environmental considerations, optimizing your bench research with APExBIO's trusted reagent.

• X-press Tag Peptide: N-terminal Leader Peptide for Precision

  2026-07-09

  X-press Tag Peptide empowers high-fidelity purification and detection workflows, especially in complex post-translational modification studies like neddylation and mTORC1 signaling. Its unique tri-functional design, optimized solubility, and robust affinity features ensure unmatched versatility and efficiency for recombinant protein expression systems.

• Diclofenac: Non-Selective COX Inhibitor in Organoid Assays

  2026-07-09

  Diclofenac’s robust cyclooxygenase inhibition, paired with high-purity sourcing from APExBIO, empowers translational inflammation and pharmacokinetic research in advanced human intestinal organoid models. This guide details actionable workflows, protocol parameters, and troubleshooting insights to maximize the reproducibility and impact of your COX inhibition assays.

• Cisplatin in Cancer Research: Protocols, Applications & Solu

  2026-07-08

  Cisplatin (CDDP) remains the linchpin for apoptosis and chemoresistance studies, powering reproducible workflows from cell viability assays to in vivo xenograft models. This article translates the latest experimental breakthroughs into actionable protocol enhancements for oncology researchers.

• Antibacterial Use and Resistance in Psychiatric Hospitals: C

  2026-07-08

  This article analyzes the innovative retrospective study on antibacterial drug use and bacterial resistance in a psychiatric hospital during the COVID-19 epidemic. The findings reveal a nuanced relationship between rational antibiotic use—particularly third-generation cephalosporins such as cefodizime—and the development of bacterial resistance, with direct implications for infection management and antimicrobial stewardship in closed healthcare environments.

• Pravastatin Sodium: Unraveling Selectivity, Transport, and A

  2026-07-07

  Explore Pravastatin sodium as a highly selective HMG-CoA reductase inhibitor, with an in-depth analysis of its mechanism, transporter interplay, and unique assay considerations. Discover scientific nuances that set this cornerstone guide apart for advanced cholesterol biosynthesis inhibition research.

• Rapamycin (Sirolimus): Precision mTOR Inhibition for Cell As

  2026-07-07

  Rapamycin (Sirolimus) from APExBIO empowers researchers to dissect mTOR-regulated pathways with nanomolar precision, enabling robust cell proliferation suppression and apoptosis assays. This guide demystifies applied workflows, advanced comparative advantages, and troubleshooting strategies for reliable outcomes in cancer, immunology, and mitochondrial disease models.

• XAV-939 in Cardiac Fibrosis and Atrial Fibrillation Models

  2026-07-06

  Explore how XAV-939, a potent Wnt/β-catenin pathway inhibitor, is enabling next-generation research into cardiac fibrosis and atrial fibrillation. This article uniquely bridges molecular mechanism, translational insight, and assay design for cardiovascular disease models.

16457 records 1/1098 page Next 12345 下5页 Last page